196 related articles for article (PubMed ID: 36614071)
21. PLGA Based Nanoparticles for the Monocyte-Mediated Anti-Tumor Drug Delivery System.
Allavena P; Palmioli A; Avigni R; Sironi M; La Ferla B; Maeda A
J Biomed Nanotechnol; 2020 Feb; 16(2):212-223. PubMed ID: 32252882
[TBL] [Abstract][Full Text] [Related]
22. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration.
Zhang X; Sun M; Zheng A; Cao D; Bi Y; Sun J
Eur J Pharm Sci; 2012 Apr; 45(5):632-8. PubMed ID: 22248882
[TBL] [Abstract][Full Text] [Related]
23. Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles.
Partikel K; Korte R; Stein NC; Mulac D; Herrmann FC; Humpf HU; Langer K
Eur J Pharm Biopharm; 2019 Aug; 141():70-80. PubMed ID: 31082511
[TBL] [Abstract][Full Text] [Related]
24. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
[TBL] [Abstract][Full Text] [Related]
25. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon.
Wu P; Zhou Q; Zhu H; Zhuang Y; Bao J
BMC Cancer; 2020 Apr; 20(1):354. PubMed ID: 32345258
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Surface-Modified PLGA Nanoparticles as a Function of Cervical Cancer Type.
Sims LB; Curry KC; Parupalli S; Horner G; Frieboes HB; Steinbach-Rankins JM
Pharm Res; 2019 Mar; 36(5):66. PubMed ID: 30868271
[TBL] [Abstract][Full Text] [Related]
27. Toxicological study of doxorubicin-loaded PLGA nanoparticles for the treatment of glioblastoma.
Pereverzeva E; Treschalin I; Treschalin M; Arantseva D; Ermolenko Y; Kumskova N; Maksimenko O; Balabanyan V; Kreuter J; Gelperina S
Int J Pharm; 2019 Jan; 554():161-178. PubMed ID: 30414476
[TBL] [Abstract][Full Text] [Related]
28. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Rahimi M; Akbarzadeh A; Zarghami N
Pharm Res; 2018 Apr; 35(6):119. PubMed ID: 29671072
[TBL] [Abstract][Full Text] [Related]
29. Neutrophil as a Carrier for Cancer Nanotherapeutics: A Comparative Study of Liposome, PLGA, and Magnetic Nanoparticles Delivery to Tumors.
Garanina AS; Vishnevskiy DA; Chernysheva AA; Valikhov MP; Malinovskaya JA; Lazareva PA; Semkina AS; Abakumov MA; Naumenko VA
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004431
[TBL] [Abstract][Full Text] [Related]
30. Microfluidic Assisted Nanoprecipitation of PLGA Nanoparticles for Curcumin Delivery to Leukemia Jurkat Cells.
Leung MHM; Shen AQ
Langmuir; 2018 Apr; 34(13):3961-3970. PubMed ID: 29544247
[TBL] [Abstract][Full Text] [Related]
31. Apoptosis-inducing peptide loaded in PLGA nanoparticles induces anti-tumor effects in vivo.
Priwitaningrum DL; Jentsch J; Bansal R; Rahimian S; Storm G; Hennink WE; Prakash J
Int J Pharm; 2020 Jul; 585():119535. PubMed ID: 32534162
[TBL] [Abstract][Full Text] [Related]
32. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles.
Panyam J; Sahoo SK; Prabha S; Bargar T; Labhasetwar V
Int J Pharm; 2003 Aug; 262(1-2):1-11. PubMed ID: 12927382
[TBL] [Abstract][Full Text] [Related]
33. Intranasal delivery of cancer-targeting doxorubicin-loaded PLGA nanoparticles arrests glioblastoma growth.
Chung K; Ullah I; Kim N; Lim J; Shin J; Lee SC; Jeon S; Kim SH; Kumar P; Lee SK
J Drug Target; 2020 Jul; 28(6):617-626. PubMed ID: 31852284
[TBL] [Abstract][Full Text] [Related]
34. Multifunctional Theranostic Nanoparticles for Enhanced Tumor Targeted Imaging and Synergistic FUS/Chemotherapy on Murine 4T1 Breast Cancer Cell.
Kang Z; Yang M; Feng X; Liao H; Zhang Z; Du Y
Int J Nanomedicine; 2022; 17():2165-2187. PubMed ID: 35592098
[TBL] [Abstract][Full Text] [Related]
35. Preparation and in vitro evaluation of doxorubicin-loaded Fe₃O₄ magnetic nanoparticles modified with biocompatible copolymers.
Akbarzadeh A; Mikaeili H; Zarghami N; Mohammad R; Barkhordari A; Davaran S
Int J Nanomedicine; 2012; 7():511-26. PubMed ID: 22334781
[TBL] [Abstract][Full Text] [Related]
36. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer.
Wang H; Zhao Y; Wang H; Gong J; He H; Shin MC; Yang VC; Huang Y
J Control Release; 2014 Oct; 192():47-56. PubMed ID: 25003794
[TBL] [Abstract][Full Text] [Related]
37. Preparation, characterization, and safety evaluation of poly(lactide-co-glycolide) nanoparticles for protein delivery into macrophages.
Guedj AS; Kell AJ; Barnes M; Stals S; Gonçalves D; Girard D; Lavigne C
Int J Nanomedicine; 2015; 10():5965-79. PubMed ID: 26445538
[TBL] [Abstract][Full Text] [Related]
38. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles.
Valencia PM; Hanewich-Hollatz MH; Gao W; Karim F; Langer R; Karnik R; Farokhzad OC
Biomaterials; 2011 Sep; 32(26):6226-33. PubMed ID: 21658757
[TBL] [Abstract][Full Text] [Related]
39. Application of temporary agglomeration of chitosan-coated nanoparticles for the treatment of lung metastasis of melanoma.
Lee SY; Koo JS; Yang M; Cho HJ
J Colloid Interface Sci; 2019 May; 544():266-275. PubMed ID: 30852352
[TBL] [Abstract][Full Text] [Related]
40. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
